Premium
Preliminary evaluation of pinacidil in hypertension.
Author(s) -
Ramsay LE,
Freestone S
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02171.x
Subject(s) - pinacidil , blood pressure , medicine , placebo , diuretic , vasodilation , anesthesia , hydrochlorothiazide , pharmacology , endocrinology , glibenclamide , alternative medicine , pathology , diabetes mellitus
In a balanced single‐blind placebo controlled study in six hypertensive patients treated with diuretic and beta‐adrenoceptor blocker, a single oral dose of 10 mg pinacidil lowered blood pressure significantly, by a maximum of 26/13 mm Hg lying and 15/12 mm Hg standing at 3 h. The duration of action was less than 6 h. Chronic treatment of four patients (mean dose 20 mg twice daily for 3–7 weeks) lowered blood pressure by only 15/7 mm Hg. All four patients experienced side‐effects of the type often observed during treatment with potent vasodilators. In the formulation studied pinacidil is unlikely to offer any advantage over the antihypertensive drugs currently available.